SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
22.60
-0.45 (-1.95%)
Dec 30, 2025, 5:29 PM CET
150.28%
Market Cap1.21B
Revenue (ttm)n/a
Net Income (ttm)-106.28M
Shares Out53.33M
EPS (ttm)-2.21
PE Ration/a
Forward PE83.98
Dividendn/a
Ex-Dividend Daten/a
Volume117,921
Average Volume118,641
Open23.00
Previous Close23.05
Day's Range22.05 - 23.05
52-Week Range8.90 - 25.30
Beta1.14
RSI57.71
Earnings DateFeb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.